Exploring longitudinal course and treatment-baseline severity interactions in secondary outcomes of smoking cessation treatment in individuals with attention-deficit hyperactivity disorder

Exploring longitudinal course and treatment-baseline severity interactions in secondary outcomes of smoking cessation treatment in individuals with attention-deficit hyperactivity disorder

Background: A double blind, placebo-controlled randomized trial (NCT00253747) evaluating osmotic-release oral system methylphenidate (OROS-MPH) for smoking-cessation revealed a significant interaction effect in which participants with higher baseline ADHD severity had better abstinence outcomes with...

Full description

Bibliographic Details
Main Authors: Covey, L. (Author), Hu, M.-C (Author), Levin, F.R (Author), Luo, S.X (Author), Nunes, E.V (Author), Scodes, J.M (Author), Wall, M. (Author), Winhusen, T. (Author)
Format: Article
Language:English
Published: Taylor and Francis Ltd 2018
Subjects:
ADHD
adolescent
adult
Adult
Article
attention deficit disorder
Attention Deficit Disorder with Hyperactivity
Central Nervous System Stimulants
central stimulant agent
complication
controlled study
craving
disease severity
double blind procedure
Double-Blind Method
drug dose escalation
female
Female
human
Humans
longitudinal
Longitudinal Studies
longitudinal study
major clinical study
male
Male
methylphenidate
Methylphenidate
middle aged
Middle Aged
nicotine
outcome assessment
placebo
psychology
randomized controlled trial
randomized controlled trial (topic)
secondary analysis
severity of illness index
Severity of Illness Index
smoking
Smoking
smoking cessation
Smoking Cessation
tobacco dependence
Tobacco Use Disorder
treatment outcome
Treatment Outcome
withdrawal
withdrawal syndrome
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items